Shots:
- The approval is based on Amulet IDE, a head-to-head study comparing Amulet with an alternative minimally invasive LAA occlusion device in patients with AFib who are at risk of ischemic stroke. The results will be presented at ESC 2021
- The device will use dual-seal technology to completely and immediately seal the LAA that helps to reduce the risk of stroke & immediately eliminating the need for blood-thinning medication
- Amplatzer Amulet Device received CE mark in 2013 & has been approved for use in 80+ countries including EU, Canada & Australia. Additionally, the device has a wide range of occluder sizes and is recapturable and repositionable to ensure optimal placement
Click here to read full press release/ article | Ref: Abbott | Image: Forbes
The post Abbott’s Amplatzer Amulet Device Receives the US FDA’s Approval for the Treatment of Atrial Fibrillation first appeared on PharmaShots.
